Health Economics›Classical Hodgkin lymphoma›Untreated early-stage unfavorable (ESU)

Untreated early-stage unfavorable (ESU)

Classical Hodgkin lymphoma · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
RABVD Variant #01 Partial	—	R 135 294	28d	—	—	~8	~R 227 497 indirect	—
A-AVD Variant #01	—	R 119 429	28d	—	—	6	R 716 574 PFS proxy	2
Stanford V Variant #01 Partial	—	R 18 121	28d	—	—	1	R 18 121 PFS proxy	1
eBEACOPP-ABVD Variant #01 Partial	—	R 9 306	28d	—	—	~2	~R 18 613 indirect	—
EBVP Variant #01 Partial	—	R 3 122	21d	—	—	~6	~R 18 734 indirect	—
ABVD Variant #01 Partial	—	R 2 885	28d	—	—	2	R 5 770 PFS proxy	4
MOPP-ABV Variant #01 Partial	—	R 2 205	28d	—	—	~8	~R 17 639 indirect	—
BEACOPP Variant #01 Partial	—	R 2 042	21d	—	—	~8	~R 16 335 indirect	—

8 of 8 regimens shown